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overall level of sanitation has improved—possibly
because children were no longer becoming infec-
ted at a young age when infection is mild and
often unrecognised. When the age at which
infection occurs increases, infection in a popula-
tion becomes more noticeable. Thus, a consider-
able potential public health burden is generated
as the distribution of HAV infection shifts to-
wards older age groups [3]. HAV is probably
transmitted by the faecal–oral route to children,
via exposure to environmental sources such as
drinking water and pit toilets or outhouses that
are contaminated with HAV. Factors such as an
excessive population density, a lack of elementary
sanitary and hygiene precautions, malnutrition
and complications with the supply of clean
drinking water all contribute to the possibility of
epidemic spread [2]. A low level of secondary
education is one indicator of a lower socio-
economic status, which is also associated with
HAV infection [10]. Preventive measures, such as
the improvement of hygiene in a defined general
population, may contribute to a reduced inci-
dence of HAV infection [8]. The development of
health promotion and prevention initiatives in
schools, as well as the introduction of rigorous
hygiene measures, will be required to achieve
acceptable control. Further studies of the cost-
effectiveness of interventions to provide safe
drinking water should address not only the
quality, but also the quantity, availability and
patterns of use, of sanitary facilities.
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A B S T R A C T
Enzyme-linked immunosorbent assays (ELISAs)
were used to detect antibodies to the C6 peptide
of the Borrelia burgdorferi VlsE protein and a
selection of B. burgdorferi IgG antigens, separately
and as a combination, in 355 serum specimens
from blood donors and patients. Western immu-
noblotting was used as the reference method. The
sensitivity of the combined analysis of IgG anti-
gen and C6 peptide analysis was markedly
superior to those of the separate analyses. When
the C6 peptide and IgG results were concordant,
the customary confirmatory Western immuno-
blotting assay could be omitted, thus reducing the
time and cost of analysis.
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There is no ideal method for routine laboratory
identification of Lyme borreliosis. Demonstration
of the Borrelia burgdorferi spirochaete by culture or
PCR is the reference method in terms of specificity,
but the sensitivity of these methods is poor.
Analysis by Western immunoblotting (WB) is
suitable for confirming the results of serological
screening methods [1,2]. A two-step approach,
comprising an enzyme-linked immunosorbent
assay (ELISA), and subsequent confirmation by
WB, has been recommended in the USA [3] and
Europe [4], but WB is time-consuming and
expensive for routine use [5]. Addition of the
Borrelia-specific protein VlsE (variable membrane
protein-like sequence, expressed) to serological
testing has been useful [6–9], and detection by
ELISA of antibodies to the C6 peptide has been
suggested for serological identification of B. burg-
dorferi [10].
The present study investigated whether the
results of C6 peptide detection, combined with
the initial ELISA results, would obviate the need
for confirmatory immunoblotting. The study was
concerned solely with methodological perform-
ance; clinical diagnosis of Lyme borreliosis al-
ways requires an evaluation of the patient’s
history, symptoms and signs, and this was not
attempted in this study.
In total, 355 serum samples were studied. These
were from individuals living on the A˚land
Islands, an area that is endemic for B. burgdorferi,
with a mean B. burgdorferi IgG prevalence of
c. 20% in the healthy population [11]. The
samples were from healthy blood donors
(n = 118) and from patients who were tested for
B. burgdorferi infection during a previous clinical
investigation (n = 237) [11]. Of the patient sera,
one group (n = 123) was analysed in an initial
hypothesis-generating step, while a second group
(n = 114) was studied prospectively and used for
validation.
C6 antibody analysis (C6-ELISA) was per-
formed with the Quick ELISA Borrelia C6 assay
(Immunetics, Cambridge, MA, USA) [12]. This
assay is based on a synthetic C6 peptide and
detects primarily IgG antibody. The IgG analysis
(IgG-ELISA) was performed with the RecomWell
Borrelia IgG assay (Mikrogen, Martinsreid, Ger-
many), in which four recombinant B. burgdorferi
antigens are utilised, namely OspC (22 kDa), a
specific internal part of the P41 (flagellin) protein,
p100 and p18 [13]. The confirmatory WB method
was the RecomBlot Borrelia IgG assay (Mikrogen)
[14], with an expected sensitivity of > 0.80 and
specificity of 0.90–0.95 [4]. In this assay, the
recombinant antigens p100, p41, BmpA, OspA,
OspC, p41 ⁄ internal Afzelii, p41 ⁄ internal Garinii
and p18 are utilised. The WB bands are graded,
favouring bands p100, BmpA and p18, and to
some extent OspC, while OspA is treated neu-
trally, and p41 and p41 ⁄ internal are downgraded
[15]. Standard statistical calculations were used
to determine specificity, sensitivity, positive
predictive value (PPV) and negative predictive
value (NPV). The chi-squared test was used for
statistical validation of the test performances
between independent groups.
For the blood donors and the first patient group
(n = 241; sample I), the IgG-ELISA vs. WB had a
sensitivity of 0.90 and a specificity of 0.80, with a
PPV of 0.65 and an NPV of 0.95. The C6-ELISA vs.
WB had a sensitivity of 0.67 and specificity of 0.98,
with a PPV of 0.92 and an NPV of 0.88. The
combination of a positive IgG-ELISA and a
positive C6-ELISA vs. WB had a sensitivity of
0.92 and a specificity of 1.00, with a PPV of 1.00
and an NPV of 0.97, indicating very good con-
cordance between these methods.
Based on these results, the hypothesis was put
forward that the combination of a positive IgG-
ELISA and a positive C6-ELISA would predict a
positive WB accurately, which would make con-
firmatory testing by WB superfluous in this
context. When the patient sera (n = 114; sample
II) in the second group were studied, the IgG-
ELISA vs. WB had a sensitivity of 0.92 and a
specificity of 0.79, with a PPV of 0.86 and an NPV
of 0.88. The C6-ELISA vs. WB had a sensitivity of
0.61 and a specificity of 0.94, with a PPV of 0.93
and an NPV of 0.63. The combination of a positive
IgG-ELISA and a positive C6-ELISA vs. WB had a
sensitivity of 0.91 and a specificity of 0.97, with a
PPV of 0.97 and an NPV of 0.95.
There was no significant difference between
samples I and II by chi-squared tests; therefore,
the results were combined and final calculations
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of performance were made on the combined
sample (n = 355). Table 1 shows the results of
the two ELISA analyses separately and as a
combination. The two methods combined had
a sensitivity of 0.91 and a specificity of 0.99, with a
PPV of 0.99 and an NPV of 0.95. These results
indicated very good concordance between the
ELISA combination and the WB method. Table 2
lists the positive reactions obtained for the differ-
ent bands in the WB analysis, and illustrates how
the two primary analyses and the WB method
complemented each other.
The results indicated that antibodies to B. burg-
dorferi, as confirmed by the WB analysis, were
demonstrated with a high degree of specificity
and sensitivity when the results of the C6-ELISA
peptide and the IgG-ELISA analyses of the sam-
ple were concordant. This was seen with 261
(73.5%) samples, while the results differed for the
remaining 94 samples. Thus, the combination
compensated for the lower sensitivity of the C6-
ELISA and the lower specificity of the IgG-ELISA.
The PPV and NPV remained high. With the
recommended two-step approach [3,4], all posit-
ive IgG-ELISA analyses (168 samples) would
need to be confirmed by WB. However, with the
combination of ELISAs, confirmation by WB
would have been necessary for only the 94
discordant samples, a decrease of 44% in work-
load.
Two of the test result combinations were of
special interest (Table 2). For eight samples, the
C6-ELISA and the IgG-ELISA were negative,
whereas WB was positive. In three of these
samples, p39 was detected with WB. This anti-
body is not recognised by the IgG-ELISA, which
explains the discrepancy. In the remaining five
samples, WB recognised bands for p100, p18
and p41 ⁄ internal, which are included in the
IgG-ELISA analysis, but the concentration of the
antibodies appeared to be below the threshold of
sensitivity claimed for the IgG-ELISA method.
A further six samples were positive by C6-ELISA,
but both the IgG-ELISA and WB were negative
because the C6 peptide is not included in the
latter two methods. This observation illustrates
the importance of choosing relevant antigens
when WB is used for serological detection of
B. burgdorferi.
Overall, it was concluded that the C6 peptide
and IgG ELISAs can be used as a first step for
detecting B. burgdorferi. If the results concur, the
confirmatory WB assay can safely be omitted,
thereby reducing laboratory workload, as well as
reducing direct costs by c. 19 euro ⁄ sample.
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Table 1. Results for Borrelia burgdorferi serology obtained
with C6 peptide and ⁄ or IgG ELISA vs. Western blot assays
(n = 355)
Western blot
Sensitivity Specificity PPV NPVPositive Negative
IgG-ELISA
Positive 124 44 0.91 0.80 0.74 0.94
Negative 12 175
C6-ELISA
Positive 87 7 0.64 0.97 0.93 0.81
Negative 49 212
C6-ELISA + IgG
concordant (n = 261)
Both positive 83 1 0.91 0.99 0.99 0.95
Both negative 8 169
C6-ELISA + IgG
discordant (n = 94)
C6 negative,
IgG positive
41 43
C6 positive,
IgG negative
4 6
NPV, negative predictive value; PPV, positive predictive value.
Table 2. Percentage of reactive Western blot bands for
each combination of test results
Analysis
n
Reactive bands, % of samples
C6 IgG WB p100 p41 p39 OspA OspC p41iBg p41iBa p18
Pos Pos Pos 83 77 72 60 5 45 35 48 88
Pos Pos Neg 1 100 100
Pos Neg Pos 4 100 100 25 50 50
Pos Neg Neg 6 83 17 34
Neg Pos Pos 42 33 62 7 5 38 17 31 60
Neg Pos Neg 42 57 2 10 10
Neg Neg Pos 8 50 50 38 12 25 12
Neg Neg Neg 169 54 4 1 4 3
C6, C6-ELISA; IgG, IgG-ELISA; WB, Western immunoblotting; Pos, positive; Neg,
negative.
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The Vitek 2 system was assessed against refer-
ence methods with 197 methicillin-resistant Sta-
phylococcus aureus from Belgian hospitals and 121
clinically significant blood culture isolates of
Staphylococcus spp. Vitek 2 identified 95% of
staphylococcal isolates correctly, detected oxacil-
lin resistance with a sensitivity/specificity of 99/
96%, and showed acceptable accuracy for sus-
ceptibility testing of five of eight other evaluable
antibiotics. The median time for reporting results
was 2 h 45 min for identification and 7 h for
susceptibility tests.
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Methicillin-resistant strains of Staphylococcus
aureus (MRSA) are important pathogens causing
nosocomial and community-acquired infections
[1]. Some coagulase-negative staphylococci
(CNS), such as Staphylococcus epidermidis and
Staphylococcus haemolyticus, are also frequently
methicillin- and multidrug-resistant [2] and cause
bloodstream and device-related infections. Inva-
sive isolates of staphylococci should therefore be
identified to the species level to determine their
clinical relevance and to monitor their epidemi-
ology [2]. Methicillin and b-lactam resistance in
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